Financhill
Back

Bolt Biotherapeutics Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Sell
42

BOLT
Bolt Biotherapeutics

Last Price:
0.64
Seasonality Move:
-17.65%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Bolt Biotherapeutics Price Quote

$0.64
-0.02 (-2.74%)
(Updated: November 6, 2024 at 11:20 AM ET)

Bolt Biotherapeutics Key Stats

Sell
42
Bolt Biotherapeutics (BOLT) is a Sell

Day range:
$0.66 - $0.67
52-week range:
$0.55 - $1.56
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.24
P/B ratio:
0.29%

Volume:
41.1K
Avg. volume:
134.7K
1-year change:
-36.12%
Market cap:
$25.2M
Revenue:
$7.9M
EPS:
$-1.74

How Much Does Bolt Biotherapeutics Make?

Is Bolt Biotherapeutics Growing As A Company?

  • What Is Bolt Biotherapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.11%
  • What Is Bolt Biotherapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Bolt Biotherapeutics Stock Price Performance

What Is Bolt Biotherapeutics 52-Week High & Low?

Bolt Biotherapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Bolt Biotherapeutics?

Is Bolt Biotherapeutics Cash Flow Positive?

  • What Is BOLT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$63.9M
  • What Is Bolt Biotherapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $0
  • What Is Bolt Biotherapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $56.7M

Bolt Biotherapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    BOLT return on invested capital is -57.72%
  • What Is Bolt Biotherapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -41.72%
  • What Is BOLT Return On Equity?
    ROE is a measure of profitability and is -57.72%

Bolt Biotherapeutics Earnings Date & Stock Price

Bolt Biotherapeutics Competitors

Bolt Biotherapeutics Dividend Yield

Bolt Biotherapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 4.55%
Revenue: -11.03% 43.02%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 1.75
Upside from Last Price: 165.96%

Major Shareholders

  • How many BOLT shares are owned by institutional investors?
    28.2M BOLT shares are owned by institutional investors
  • How many BOLT shares are owned by insiders?
    133.8K BOLT shares are owned by insiders